Extended Data Fig. 1: Participant disposition flow chart describing dosing strategy and discontinuations. | Nature Medicine

Extended Data Fig. 1: Participant disposition flow chart describing dosing strategy and discontinuations.

From: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Extended Data Fig. 1

Participants were randomized 6:2 to LY3475766 or placebo (0.9% sodium chloride) in each cohort. The 300 mg dose group included 12 participants treated with LY3475766 due to restarting during the COVID-19 pandemic. IV, intravenous; LY, LY3475766; n, number of participants; SC, subcutaneous.

Back to article page